Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

NCT07140900 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07140900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07140900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Recruiting
Start date
October 7, 2025
Completion date
March 30, 2030
Enrollment
60 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer (mhspc)